|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1305066150 |
| 003 |
OCoLC |
| 005 |
20231120010637.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
220323s2022 mau o 000 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCO
|d EBLCP
|d OCLCF
|d YDX
|d UKMGB
|d SFB
|d UKAHL
|d OCLCQ
|
| 015 |
|
|
|a GBC208694
|2 bnb
|
| 016 |
7 |
|
|a 020452291
|2 Uk
|
| 019 |
|
|
|a 1304815609
|a 1305011403
|a 1305166106
|a 1351993670
|
| 020 |
|
|
|z 9780323992275
|
| 020 |
|
|
|a 9780323992282
|q (electronic bk.)
|
| 020 |
|
|
|a 0323992285
|q (electronic bk.)
|
| 020 |
|
|
|z 0323992277
|
| 035 |
|
|
|a (OCoLC)1305066150
|z (OCoLC)1304815609
|z (OCoLC)1305011403
|z (OCoLC)1305166106
|z (OCoLC)1351993670
|
| 050 |
|
4 |
|a RM275
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 245 |
0 |
0 |
|a Immunotherapeutics /
|c Edited by Rossen Donev.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource (1 volume)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Advances in protein chemistry and structural biology ;
|v 129
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Immunotherapeutics -- Copyright -- Contents -- Contributors -- Chapter One: In silico tools and databases for designing cancer immunotherapy -- 1. Introduction -- 2. Cancer associated genomic data -- 2.1. Genome profile repositories -- 2.2. Mutation profile databases -- 2.3. Cancer biomarker repositories -- 3. Immunological database -- 4. Analysis of genomic profiles -- 5. Prediction of cancer biomarkers -- 6. Identification of vaccine candidates -- 6.1. B-cell epitope -- 6.2. MHC binders -- 6.3. T-cell epitope -- 6.4. Cytokines inducing peptides -- 6.5. Neoepitope for cancer
|
| 505 |
8 |
|
|a 7. Important pipelines -- 7.1. HLA typing -- 7.2. Neoantigen -- 8. Cancer-specific immunotherapy -- 9. Miscellaneous -- 10. Discussion and conclusion -- Acknowledgments -- References -- Chapter Two: Immunotherapeutic approaches for HPV-caused cervical cancer -- 1. Introduction -- 2. HPV -- 2.1. Structure -- 2.2. HPV types -- 2.3. Viral life cycle and pathogenesis -- 2.4. Immune response to HPV infection -- 3. Vaccines -- 4. HPV therapeutic vaccines -- 4.1. Peptide-/protein-based vaccines -- 4.2. Vector-based vaccines -- 4.3. Nano-delivery systems -- 4.4. DNA-based vaccines
|
| 505 |
8 |
|
|a 4.5. RNA-based vaccines -- 4.6. Cell-based vaccines -- 4.6.1. Dendritic cell-based vaccines -- 4.6.2. Tumor-cell-based vaccines -- 4.6.3. Adoptive T-cell therapy -- 4.7. Therapeutic HPV vaccines in combination with therapeutic modalities -- 4.7.1. Therapeutic HPV vaccines accompanied by immune checkpoint blockade -- 4.7.2. Therapeutic HPV vaccines along with chemo-immunotherapy and radiotherapy -- 4.7.3. Therapeutic HPV vaccines in combination with other treatment modalities -- 5. Conclusion -- Funding -- Conflicts of interest -- References
|
| 505 |
8 |
|
|a Chapter Three: Natural killer cell-based strategies for immunotherapy of cancer -- 1. Natural killer cells origin and functions -- 2. NK cell recognition in health and disease -- 2.1. NK cell receptor families -- 2.1.1. C-type lectin-like receptors -- 2.1.2. Killer immunoglobulin-like receptors -- 2.1.3. Natural cytotoxicity receptors -- 3. NK cells as a tool of cancer immunotherapy -- 3.1. Cancer immunosurveillance -- 3.2. Mechanisms of tumor escape from NK cell immunosurveillance -- 4. NK cell-based immunotherapeutics -- 4.1. Activated NK cell-based therapeutics
|
| 505 |
8 |
|
|a 4.2. Recombinant protein-based NK cell therapeutics -- 4.3. Gene-modified NK cell-based therapeutics -- 5. Concluding remarks -- Acknowledgments -- References -- Chapter Four: Noncoding RNAs as novel immunotherapeutic tools against cancer -- 1. Introduction -- 2. Immunotherapy in human diseases -- 3. Immunotherapy in cancer -- 4. Noncoding RNAs in cancer -- 4.1. Reprogramming of macrophage differentiation & function by ncRNAs -- 4.2. Modulation of natural killer cell mediated cytotoxicity by ncRNAs -- 4.3. Regulation of neutrophil plasticity & activity by ncRNAs
|
| 650 |
|
0 |
|a Immunotherapy.
|
| 650 |
|
2 |
|a Immunotherapy
|0 (DNLM)D007167
|
| 650 |
|
6 |
|a Immunoth�erapie.
|0 (CaQQLa)201-0067406
|
| 650 |
|
7 |
|a Immunotherapy.
|2 fast
|0 (OCoLC)fst00968044
|
| 700 |
1 |
|
|a Donev, Rossen,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t IMMUNOTHERAPEUTICS.
|d [Place of publication not identified] : ELSEVIER ACADEMIC PRESS, 2022
|z 0323992277
|w (OCoLC)1264711987
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/18761623/129
|z Texto completo
|
